DX Dialogues: New treatment advances & future treatments
Jennifer Dilts, DO, shares the latest advances in treating pediatric migraines and offers insights into promising future therapies for young patients.
Transcript
Recent trials have shown that with these new targeted therapies, we have fewer migraine days compared
to our standard therapies. [MUSIC PLAYING]
One exciting advance in recent years is targeting CGRP. We know that CGRP has a large role in migraine propagation,
and we have targeted drugs that interfere with that CGRP receptor and the binding of that protein to its receptor.
And this can stop a migraine and oftentimes prevent migraines as well. So with precision medicine, we're
able to analyze someone's genotype, their genetics, and know which medications are going
to be metabolized in a way that makes them effective and potentially even then go a step further and predict which
medications are most effective for each patient. It's really important that we have long-term safety data,
because some of these children are starting migraine treatments as young as age six. And so, of course, as physicians and talking with parents,
we want to make sure that these drugs are well studied in the long term. It's really important, and we know that from studies,
that the delivery route is really important to our pediatric patients and their parents. [AUDIO LOGO]
migraines
Browse videos by topic categories
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
ALL